63.8 F
Pakistan
Saturday, March 28, 2026
HomeHealthBiomednewsbreaks - Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For...
Health

Biomednewsbreaks – Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

muhammadhasan0426@gmail.com
By muhammadhasan0426@gmail.com
0
5

(MENAFN – Investor Brand Network) Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behc–et Disease, .. .

Read full story on Menafn

Previous article
Advisory Body Says US AI Lead At Risk As China Dominates Open-Source AI
Next article
Experts Highlight The Emissions Increases Arising From The Iran Conflict
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Load more

Recent Comments

GrowthPakistan brings you the latest news to keep an eye on Pakistan’s startup ecosystem. Business keeps you growing when you stay aware of your competitors' moves. GrowthPakistan offers Business, Tech, Global Tech, Global, Auto, and Startup News straight from industries all around the globe. This platform will help you identify upcoming opportunities not only in Pakistan but worldwide.

Email : growthpakistan@gmail.com
Whatsapp : +92320-9497079

© growthpakistan